Skip to main content

Table 3 Variables associated with PFS in patients with clinical benefit

From: BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma

 

N

Median PFS (in months)

Univariable Analysis

Multivariable Analysis

HR (95% CI)

p-value

HR (95% CI)

p-value

Age

52

16.24

0.95 (0.91, 1.00)

0.06

  

BMI

52

16.24

0.90 (0.82, 0.98)

0.02

0.87 (0.79, 0.96)

0.007

Smoking history

 No

27

13.28

1.00

Ref

  

 Yes

25

18.48

0.80 (0.39, 1.67)

0.55

  

Nephrectomy

 Total

44

16.24

Ref

Ref

  

 Partial

3

–

0.31 (0.04, 2.45)

0.27

  

 None

5

18.48

0.83 (0.25, 2.78)

0.76

  

ICI line of treatment

 First line

5

–

1.00

Ref

  

 Second line

23

18.48

1.73 (0.37, 8.08)

0.49

  

 Third line

17

13.28

2.65 (0.54, 13.04)

0.23

  

 Fourth line

5

20.52

2.08 (0.32, 13.56)

0.44

  

 > 4 prior treatments

2

25.71

0.83 (0.07, 9.45)

0.88

  

ECOG PS at start of immunotherapy

 0

19

16.24

1.00

Ref

  

 1 or 2 or 3

32

18.48

0.83 (0.38, 1.79)

0.63

  

 Missing

1

–

–

–

  

IMDC risk score

 Favorable

13

16.44

1.00

Ref

  

 Intermediate

32

14.83

1.43 (0.58, 3.53)

0.44

  

 Poor

3

26.86

0.29 (0.04, 2.38)

0.25

  

Occurrence of irAE

 No

33

10.13

1.00

Ref

1.00

Ref

 Yes

19

20.52

0.42 (0.17, 0.99)

0.04

0.33 (0.13, 0.82)

0.02